This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoffman, H. L.
Right arrow Articles by Doern, G. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoffman, H. L.
Right arrow Articles by Doern, G. V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2003, p. 739-746, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.739-746.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Influence of Macrolide Susceptibility on Efficacies of Clarithromycin and Azithromycin against Streptococcus pneumoniae in a Murine Lung Infection Model

Holly L. Hoffman,1 Michael E. Klepser,2* Erika J. Ernst,1 C. Rosemarie Petzold,1 Loai Mohammed Sa'adah,1 and Gary V. Doern3

Colleges of Pharmacy,1 Medicine, University of Iowa, Iowa City, Iowa,3 Ferris State University College of Pharmacy, Big Rapids, Michigan2

Received 16 May 2001/ Returned for modification 11 November 2001/ Accepted 30 October 2002

We evaluated the activities of clarithromycin and azithromycin against 19 isolates of Streptococcus pneumoniae using a neutropenic lung infection model. The isolates included five susceptible isolates (clarithromycin and azithromycin MICs, <=0.12 µg/ml), nine isolates exhibiting low-level, mefA-mediated resistance (clarithromycin and azithromycin MICs, 0.5 to 32 µg/ml), and five isolates expressing high-level, ermB-mediated macrolide resistance (clarithromycin and azithromycin MICs, >=64 µg/ml). Infected mice were administered either saline (control), clarithromycin (4, 40, or 200 mg/kg of body weight twice daily or 200 mg/kg once daily), or azithromycin (4, 40, or 200 mg/kg once daily or 40 mg/kg twice daily) by oral gavage for 72 h. Mortality was assessed at regular intervals for 10 days, and survival in each group was compared to that of untreated controls. Animals infected with susceptible isolates demonstrated significant improvement in survival compared to the controls following treatment with either agent at doses of >=40 mg/kg. In contrast, none of the regimens improved the survival of animals infected with isolates exhibiting high-level macrolide resistance. Among mice infected with strains expressing low-level resistance, significant improvement in survival compared to the controls was noted among isolates treated with clarithromycin at 40 (seven of nine isolates) and 200 (nine of nine isolates) mg/kg twice a day and with azithromycin at 40 (one of nine isolates) and 200 (three of nine isolates) mg/kg once a day. Animals infected with isolates of S. pneumoniae exhibiting low-level, mefA-mediated macrolide resistance responded to treatment with clarithromycin at rates similar to those observed among mice infected with fully susceptible isolates.

* Corresponding author. Mailing address: Department of Pharmacy, Borgess Medical Center, Ferris State University College of Pharmacy, 1521 Gull Rd., Kalamazoo, MI 49048. Phone: (269) 226-5798. Fax: (269) 226-8173. E-mail: mklepser{at}borgess.com.

Antimicrobial Agents and Chemotherapy, February 2003, p. 739-746, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.739-746.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Yasuda, Y., Kasahara, K., Mizuno, F., Nishi, K., Mikasa, K., Kita, E. (2007). Roxithromycin Favorably Modifies the Initial Phase of Resistance against Infection with Macrolide-Resistant Streptococcus pneumoniae in a Murine Pneumonia Model. Antimicrob. Agents Chemother. 51: 1741-1752 [Abstract] [Full Text]  
  • Farrell, D. J., File, T. M., Jenkins, S. G. (2007). Prevalence and Antibacterial Susceptibility of mef(A)-Positive Macrolide-Resistant Streptococcus pneumoniae over 4 Years (2000 to 2004) of the PROTEKT US Study. J. Clin. Microbiol. 45: 290-293 [Abstract] [Full Text]  
  • Fukuda, Y., Yanagihara, K., Higashiyama, Y., Miyazaki, Y., Hirakata, Y., Mukae, H., Tomono, K., Mizuta, Y., Tsukamoto, K., Kohno, S. (2006). Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 27: 1020-1025 [Abstract] [Full Text]  
  • Sun, H. K., Lee, S. Y., Banevicius, M. A., Du, X., Maglio, D., Nicolau, D. P. (2005). Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model. J Antimicrob Chemother 56: 559-565 [Abstract] [Full Text]  
  • Nuermberger, E. L., Bishai, W. R. (2003). Significance of macrolide resistance in Streptococcus pneumoniae. J Antimicrob Chemother 52: 524-525 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»